New York State Common Retirement Fund Cuts Position in Silk Road Medical, Inc (NASDAQ:SILK)

New York State Common Retirement Fund lowered its holdings in shares of Silk Road Medical, Inc (NASDAQ:SILK - Free Report) by 79.4% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 13,931 shares of the company's stock after selling 53,640 shares during the period. New York State Common Retirement Fund's holdings in Silk Road Medical were worth $171,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Swiss National Bank boosted its position in Silk Road Medical by 1.7% during the third quarter. Swiss National Bank now owns 85,200 shares of the company's stock valued at $1,277,000 after acquiring an additional 1,400 shares during the last quarter. CWM LLC raised its holdings in shares of Silk Road Medical by 151.5% during the fourth quarter. CWM LLC now owns 2,563 shares of the company's stock valued at $31,000 after purchasing an additional 1,544 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Silk Road Medical by 28.3% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,295 shares of the company's stock worth $139,000 after purchasing an additional 2,049 shares in the last quarter. RiverPark Advisors LLC acquired a new stake in shares of Silk Road Medical in the 3rd quarter valued at about $34,000. Finally, Asset Management Resources LLC increased its position in Silk Road Medical by 44.3% in the 3rd quarter. Asset Management Resources LLC now owns 11,588 shares of the company's stock valued at $174,000 after buying an additional 3,560 shares in the last quarter.

Insider Buying and Selling at Silk Road Medical

In other Silk Road Medical news, Director Kevin J. Ballinger acquired 11,700 shares of the business's stock in a transaction that occurred on Tuesday, March 5th. The stock was bought at an average cost of $16.99 per share, with a total value of $198,783.00. Following the acquisition, the director now owns 17,807 shares in the company, valued at $302,540.93. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other news, CAO Marie L. Jones sold 2,602 shares of the stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $17.17, for a total value of $44,676.34. Following the sale, the chief accounting officer now directly owns 76,894 shares of the company's stock, valued at $1,320,269.98. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Kevin J. Ballinger acquired 11,700 shares of the business's stock in a transaction dated Tuesday, March 5th. The stock was purchased at an average price of $16.99 per share, with a total value of $198,783.00. Following the completion of the transaction, the director now directly owns 17,807 shares of the company's stock, valued at approximately $302,540.93. The disclosure for this purchase can be found here. Insiders have sold a total of 20,457 shares of company stock valued at $351,247 over the last three months. 6.70% of the stock is currently owned by insiders.

Silk Road Medical Stock Performance

Shares of Silk Road Medical stock traded down $0.27 on Friday, reaching $22.18. 491,374 shares of the company traded hands, compared to its average volume of 633,560. The company has a debt-to-equity ratio of 0.52, a current ratio of 11.05 and a quick ratio of 9.62. The firm has a market capitalization of $874.78 million, a PE ratio of -16.19 and a beta of 1.43. The company has a 50 day moving average of $18.53 and a 200 day moving average of $14.60. Silk Road Medical, Inc has a 52 week low of $6.08 and a 52 week high of $34.13.

Silk Road Medical (NASDAQ:SILK - Get Free Report) last released its earnings results on Tuesday, April 30th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.40) by $0.04. The business had revenue of $48.50 million during the quarter, compared to the consensus estimate of $44.67 million. Silk Road Medical had a negative return on equity of 35.47% and a negative net margin of 29.02%. The business's revenue for the quarter was up 20.9% on a year-over-year basis. During the same period last year, the business posted ($0.43) earnings per share. Equities analysts forecast that Silk Road Medical, Inc will post -1.43 earnings per share for the current year.

Wall Street Analysts Forecast Growth

SILK has been the subject of a number of analyst reports. JPMorgan Chase & Co. lifted their price objective on shares of Silk Road Medical from $19.00 to $21.00 and gave the company a "neutral" rating in a report on Wednesday, May 1st. Piper Sandler upped their price target on Silk Road Medical from $18.00 to $20.00 and gave the stock a "neutral" rating in a report on Wednesday, May 1st. Stifel Nicolaus raised their price objective on Silk Road Medical from $20.00 to $23.00 and gave the company a "buy" rating in a research note on Thursday, February 29th. Finally, Argus upgraded shares of Silk Road Medical from a "hold" rating to a "buy" rating and set a $24.00 target price for the company in a research note on Thursday, March 7th. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Hold" and an average target price of $22.55.

About Silk Road Medical

Silk Road Medical, Inc operates as a medical device company in the United States. The company offers various products for the treatment of carotid artery disease called transcarotid artery revascularization (TCAR). Its products comprise ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and establish temporary blood flow reversal; ENROUTE Transcarotid Stent System for transcarotid access; ENHANCE Transcarotid Peripheral Access Kit, which is used to gain initial access to the common carotid artery; ENROUTE 0.014 Guidewire for atraumatic vessel navigation and target lesion crossing for delivery of interventional devices; and ENROUTE Enflate Transcarotid RX Balloon Dilation Catheter, a transcarotid rapid exchange balloon for the TCAR procedure.